Aemetis (AMTX) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMTX, but not buy additional shares or sell existing shares.
View AMTX analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month target prices for Aemetis' stock. Their AMTX share price forecasts range from $2.50 to $28.00. On average, they expect the company's share price to reach $13.42 in the next year. This suggests a possible upside of 220.2% from the stock's current price.
View analysts price targets for AMTX or view top-rated stocks among Wall Street analysts.

Aemetis' stock was trading at $3.96 at the start of the year. Since then, AMTX shares have increased by 5.8% and is now trading at $4.19.
View the best growth stocks for 2023 here.

Aemetis saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,690,000 shares, an increase of 20.3% from the August 15th total of 3,900,000 shares. Based on an average daily trading volume, of 734,700 shares, the days-to-cover ratio is currently 6.4 days.
View Aemetis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AMTX earnings forecast.

Aemetis, Inc. (NASDAQ:AMTX) issued its quarterly earnings results on Thursday, August, 3rd. The specialty chemicals company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.40. The specialty chemicals company earned $45.11 million during the quarter, compared to the consensus estimate of $67.30 million.

Invesco Dorsey Wright Energy Momentum ETF holds 189,235 shares of AMTX stock, representing 1.60% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Tilly's (TLYS), Auxly Cannabis Group (CBWTF), Novan (NOVN), Aeterna Zentaris (AEZS), American Cannabis (AMMJ) and Bionano Genomics (BNGO).

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Aemetis' stock is owned by many different institutional and retail investors. Top institutional investors include Encompass Capital Advisors LLC (4.65%), BlackRock Inc. (1.44%), Stifel Financial Corp (1.13%), Geode Capital Management LLC (0.80%), Citadel Advisors LLC (0.00%) and State Street Corp (0.35%). Insiders that own company stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Naomi Louise Boness, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends.

Shares of AMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMTX stock can currently be purchased for approximately $4.19.

Aemetis (NASDAQ:AMTX) has a market capitalization of $162.78 million and generates $256.51 million in revenue each year. The specialty chemicals company earns $-107,760,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.

The company employs 167 workers across the globe.

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The official website for the company is www.aemetis.com. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at investors@aemetis.com, or via fax at 408-252-8044.